BMC Cancer最新文献

{"title":"Resolution of oncogene-induced senescence markers in HPV-infected cervical cancer tissue.","authors":"Ashraf I Khasawneh, Sofian Al Shboul, Nisreen Himsawi, Amani Al Rousan, Nisreen Abu Shahin, Mohammed El-Sadoni, Ahmad Alhesa, Ala' Abu Ghalioun, Suzan Khawaldeh, Bayan Shawish, Salem Abu Mahfouz, Mais Al-Shayeb, Shatha Abo Dawoud, Raghad Tlilan, Mohammad Nuseir, Moureq R Alotaibi, Ola Abu Al Karsaneh, Fida Asali, Marcos Yébenes Mayordomo, Raghda Barham, Rame Khasawneh, Tareq Saleh","doi":"10.1186/s12885-025-13499-0","DOIUrl":"https://doi.org/10.1186/s12885-025-13499-0","url":null,"abstract":"<p><strong>Background: </strong>Oncogene-Induced Senescence (OIS) is a form of senescence that occurs as a consequence of oncogenic overstimulation and possibly infection by oncogenic viruses. Whether senescence plays a role in the pathogenesis of cervical cancer (CC) is not well understood. Moreover, whether cervical epithelial cells that are part of the premalignant cervical intraepithelial neoplasia (CIN), exhibit markers of OIS in Human Papillomavirus (HPV)-infected tissue, has not been investigated.</p><p><strong>Methods: </strong>We utilized a set of patient-derived premalignant and malignant tissue samples to investigate the protein (Ki67 and Lamin B1) and gene (TP53, IL1A, CCL2, and MMP9) expression of several OIS-associated biomarkers using immunohistochemistry (IHC) and qRT-PCR, respectively. Furthermore, we characterized the HPV status of all tissue samples.</p><p><strong>Results: </strong>Most of the CC samples (34/37) were positive for HPV, mainly HPV-16 which was observed in 62.2% of the CC samples. Among CINs, HPV infection was found in 60.2% of the 32 samples with HPV-16 as the dominant genotype in 58.5% of the CINs. IHC analysis revealed a significant increase in the expression levels of both Ki67 and Lamin B1 proteins in CC tissue compared to CIN. On average, 93% of tumor cells were positive for Ki67 in comparison to only 25% of premalignant cells in CIN samples. Similarly, Lamin B1 expression was observed in 89% of tumor cells in malignant tissue on average, compared to 60% in CIN samples. Importantly, Lamin B1 expression was elevated in nonmalignant cervical tissue suggesting that its downregulation is more predominant in the premalignant state. Furthermore, RT-PCR revealed a significant decrease in the expression of TP53, IL1a, CCL2, and MMP9 markers in CC samples compared to CINs. Specifically, 84% of CC samples showed reduced TP53 expression, 90% showed reduced IL1a expression, 74% showed reduced CCL2 expression, and 76% showed reduced MMP9 expression when compared with their premalignant baseline. Infection of HPV was confirmed in 61% of the tumor tissues while only 25% of the CINs were positive for HPV.</p><p><strong>Conclusion: </strong>This work shall provide an opportunity to further examine the role of OIS in the process of HPV-driven CC development.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"111"},"PeriodicalIF":3.4,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3D synergistic tumor-liver analysis further improves the efficacy prediction in hepatocellular carcinoma: a multi-center study.","authors":"Yurong Jiang, Jiawei Zhang, Zhaochen Liu, Jinxiong Zhang, Xiangrong Yu, Danyan Lin, Dandan Dong, Mingyue Cai, Chongyang Duan, Shuyi Liu, Wenhui Wang, Yuan Chen, Qiyang Li, Weiguo Xu, Meiyan Huang, Sirui Fu","doi":"10.1186/s12885-025-13501-9","DOIUrl":"https://doi.org/10.1186/s12885-025-13501-9","url":null,"abstract":"<p><strong>Background: </strong>Besides tumorous information, synergistic liver parenchyma assessments may provide additional insights into the prognosis of hepatocellular carcinoma (HCC). This study aimed to investigate whether 3D synergistic tumor-liver analysis could improve the prediction accuracy for HCC prognosis.</p><p><strong>Methods: </strong>A total of 422 HCC patients from six centers were included. Datasets were divided into training and external validation datasets. Besides tumor, we also performed automatic 3D assessment of liver parenchyma by extracting morphological and high-dimensional data, respectively. Subsequently, we constructed a tumor model, a tumor-liver model, a clinical model and an integrated model combining information from clinical factors, tumor and liver parenchyma. Their discrimination and calibration were compared to determine the optimal model. Subgroup analysis was conducted to test the robustness, and survival analysis was conducted to identify high- and low-risk populations.</p><p><strong>Results: </strong>The tumor-liver model was superior to the tumor model in terms of both discrimination (training dataset: 0.747 vs. 0.722; validation dataset: 0.719 vs. 0.683) and calibration. Moreover, the integrated model was superior to the clinical model and tumor-liver model, particularly in discrimination (training dataset: 0.765 vs. 0.695 vs. 0.747; validation dataset: 0.739 vs. 0.628 vs. 0.719). The AUC of the integrated model was not influenced by AFP level, BCLC stage, Child-Pugh grade, and treatment style in training (6 months p value: 0.245-0.452; 12 months p value: 0.357-0.845) and validation (6 months p value: 0.294-0.638; 12 months p value: 0.365-0.937) datasets. With a risk score of 1.06, high- and low-risk populations demonstrated significant difference for progression-free survival (p < 0.001 in both datasets).</p><p><strong>Conclusions: </strong>Combined with clinical factors, 3D synergistic tumor-liver assessment improved the efficacy prediction of HCC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"108"},"PeriodicalIF":3.4,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gross recurrent laryngeal nerve invasion by extranodal extension in thyroid carcinoma.","authors":"Xin Li, Xiang-Yun Yao, Shi-Rong Liu, Fang Mei, Bo Yu, Bing-Yan Wang, Shi-Bing Song, Shi Tan","doi":"10.1186/s12885-025-13500-w","DOIUrl":"https://doi.org/10.1186/s12885-025-13500-w","url":null,"abstract":"<p><strong>Background: </strong>Lymphatic metastasis commonly occurs in patients with papillary thyroid carcinoma and medullary thyroid carcinoma. The clinical and imaging characteristics of recurrent laryngeal nerve (RLN) invasion by extranodal extension (ENE) of metastatic lymph nodes remain understudied. This study aimed to evaluate these characteristics in patients with thyroid carcinoma.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on 77 patients treated between January 2012 and March 2024 with thyroid carcinoma demonstrating gross RLN invasion during surgery. Fifteen patients with gross RLN invasion by ENE of the metastatic lymph nodes were included. The primary endpoint was the percentage of preserved nerves. The secondary endpoints included vocal cord function and recurrence-free survival.</p><p><strong>Results: </strong>Fourteen patients had papillary thyroid carcinoma (PTC), and one had medullary thyroid carcinoma (MTC). There was no case of distant metastasis in the series. In the PTC group, two patients presented with hoarseness. There were two (14.3%) cases of T1a, six (42.9%) cases of T1b, and nine (64.3%) cases with concomitant lateral lymph node metastasis. The stage of the MTC case was T3bN1a. Among all the cases included, ten (67.7%) and five (33.3%) right and left RLNs, respectively, were invaded by ENE of the central compartment lymph nodes. Ultrasonography showed lymph nodes wrapping beyond half of the circumference of the RLNs and indistinct boundaries between the nodes and RLNs. Seven patients (46.7%) had the tumor shaved off from the epineurium, and three (20.0%) had the integrity of the RLNs preserved with gross residual tumor. Permanent vocal cord paralysis occurred in two (13.3%) cases receiving neurectomy, of which one was of the PTC group, and the other one belonged to the MTC group. At the end of the follow-up period, two patients in the PTC group experienced locoregional recurrence.</p><p><strong>Conclusions: </strong>Most patients with RLN invasion by ENE were asymptomatic. Sonography is feasible for assessing the location of metastatic lymph nodes in relation to the RLN in this preliminary study. Careful central compartment evaluation for patients with lymphatic metastases from thyroid carcinoma is conducive to nerve preservation and radical resection of lesions, especially for patients with MTC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"109"},"PeriodicalIF":3.4,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TGF-β signaling orchestrates cancer-associated fibroblasts in the tumor microenvironment of human hepatocellular carcinoma: unveiling insights and clinical significance.","authors":"Junwei Ge, Hongwei Jiang, Junjun Chen, Xuemin Chen, Yue Zhang, Liangrong Shi, Xiao Zheng, Jingting Jiang, Lujun Chen","doi":"10.1186/s12885-025-13435-2","DOIUrl":"https://doi.org/10.1186/s12885-025-13435-2","url":null,"abstract":"<p><p>Liver cancer, specifically hepatocellular carcinoma (HCC), stands out as one of the most formidable solid tumors, characterized by a dauntingly low survival rate. At the forefront of the tumor microenvironment (TME) orchestrating the initiation and advancement of HCC are cancer-associated fibroblasts (CAFs). TGF-β, widely recognized as a potent activator of CAFs, not only regulates their activity but also assumes a pivotal role in the metastatic journey of the tumor. In our recent study, drawing from the GEO database, we identified two fibroblast subtypes in HCC through single-cell RNA sequencing (scRNA-seq) and explore the expression and distribution of TGF-β and its receptors in the TME of HCC. Subsequently, we investigated the interactions between tumor cells expressing high levels (TGFB1^high) and low levels (TGFB1^low) of TGF-β in the HCC TME and the two subtypes of CAFs. We also employed multi-color immunohistochemistry (mIHC) technology to examine the expressions of FAP, α-SMA, CD4, Foxp3, and TGF-β in HCC tissues within a tissue microarray. Additionally, we analyzed clinical associations, prognostic values, and the correlation of these molecules. These insights advance our understanding of the molecular mechanisms driving HCC progression and underscore the intricate interplay between tumor cells and the stromal components of the TME.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"113"},"PeriodicalIF":3.4,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of molecular targeted therapies in nasopharyngeal carcinoma: a network meta-analysis.","authors":"Htet Htet, Jwala Rebacca James Anaghan, Heethal Jaiprakash, Ismail Abdul Sattar Burud, Thiruselvi Subramaniam, Igor Iezhitsa, Renu Agarwal","doi":"10.1186/s12885-025-13528-y","DOIUrl":"https://doi.org/10.1186/s12885-025-13528-y","url":null,"abstract":"<p><strong>Background: </strong>Nasopharyngeal carcinoma (NPC) is one of the most common head and neck cancers worldwide. The majority of the new cases were from Asia and are the leading cause of cancer in China. The main treatment is surgery and radiotherapy with chemotherapy for advanced cases. With the advancement of targeted therapies, the objective of this study was to investigate the efficacy and safety of targeted therapies in NPC.</p><p><strong>Methods: </strong>Databases were searched from inception to Aug 2023, comparing molecular targeted therapies (MTT) with conventional chemotherapy, chemotherapy or surgery. Study screening, data extraction, and data analysis were conducted independently by two investigators. The Cochrane Risk of Bias tool 1.0 was used for the quality of the studies.</p><p><strong>Results: </strong>There was a total of ten eligible studies with 471 participants in the treatment arm and 469 participants in the control arm. Most studies had an unclear risk of bias assessment. Upon network meta-analysis, cetuximab was found to be the most effective regimen for complete response (CR), bevacizumab was found to be the most effective regimen for partial response (PR), nimotuzumab was found to be the most effective regimen for overall survival rate (OS) and progression-free survival (PFS). Pairwise meta-analysis showed that MTT had a significantly better response than conventional therapies in complete response. GRADE analysis reported low certainty of evidence for CR and very low certainty of evidence for other efficacy outcomes. There was a higher chance of bleeding with MTT and was statistically significant.</p><p><strong>Conclusion: </strong>It was observed that targeted therapies were found to be a promising strategy for NPC especially recurrent and/or metastatic NPC, but the most appropriate therapy still needs to be evaluated.</p><p><strong>Trial registration: </strong>This study was registered with the International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY) with a registration number of INPLASY202380024.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"110"},"PeriodicalIF":3.4,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nomogram for prognosis prediction in metastatic pancreatic cancer patients undergoing intra-arterial infusion chemotherapy: incorporating immune-inflammation scores and coagulation indicators.","authors":"Yifan Yang, Shaoqi Zong, Yongqiang Hua","doi":"10.1186/s12885-025-13523-3","DOIUrl":"https://doi.org/10.1186/s12885-025-13523-3","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer is one of the most malignant tumors with an inferior prognosis. This study aims to determine the prognostic significance of immune-inflammatory scores and coagulation indices in patients with metastatic pancreatic cancer(MPC) and develop a predictive nomogram.</p><p><strong>Methods: </strong>This study retrospectively analyzed the clinical data of 384 patients with MPC who underwent intra-arterial infusion chemotherapy (IAIC). Patients were randomly divided into training and validation cohorts. Firstly, the optimal cutoff values for continuous variables were obtained in the training cohort. Then, survival analysis was performed to evaluate the impact of immune-inflammatory scores neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and coagulation indicators prothrombin time (PT), fibrinogen (FIB), and D-dimer on the overall survival (OS) of patients. Next, univariate analysis was utilized to identify prognostic factors, and a stepwise regression method was employed for variable selection to construct a nomogram based on the Cox proportional hazards model. Additionally, the predictive performance of the nomogram was assessed by the concordance index (C-index), the area under the ROC curve (AUC), and calibration curves. Finally, patients were stratified into risk groups based on the total score of the nomogram.</p><p><strong>Results: </strong>The Kaplan-Meier survival curves indicated that immune-inflammatory scores NLR, PLR, SII, and coagulation indicators PT, FIB, and D-dimer were associated with OS. Through Cox regression analysis, a nomogram was ultimately constructed incorporating NLR, PLR, PT, alkaline phosphatase (ALP), carbohydrate antigen 125 (CA125), age, and ablation. The model demonstrated good discriminative ability, with a C-index of 0.722, and the AUC values at 6- and 12-month OS predictions were 0.828 and 0.851 in the training cohort, while in the validation cohort, the corresponding AUC values were 0.754 and 0.791, respectively. The calibration curves showed a good fit, confirming the stability of the model. A cutoff value of 353.3 was identified as optimal for risk stratification, with a statistically significant difference in OS between the high- and low-risk groups.</p><p><strong>Conclusion: </strong>The nomogram based on immune-inflammatory scores, coagulation indicators, and other clinicopathological factors can effectively predict the OS of patients with MPC.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"107"},"PeriodicalIF":3.4,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new prognostic model for predicting overall survival and progression-free survival in unresectable hepatocellular carcinoma treated with the FOLFOX-HAIC regimen based on patient clinical characteristics and blood biomarkers.","authors":"Qiuyao Zeng, Zehong Zhou, Ji Zhang, Rongzeng Cai, Hongwei Yang, Pengfei Chen, Linfang Li","doi":"10.1186/s12885-024-13390-4","DOIUrl":"https://doi.org/10.1186/s12885-024-13390-4","url":null,"abstract":"<p><strong>Background: </strong>We developed a prognostic model to evaluate the overall survival (OS) and progression-free survival (PFS) of patients with unresectable hepatocellular carcinoma (u-HCC) treated with Hepatic arterial infusion chemotherapy of infusion oxaliplatin, fluorouracil and leucovorin (FOLFOX-HAIC).</p><p><strong>Methods: </strong>This model was based on a retrospective study of u-HCC patients treated with the FOLFOX-HAIC (oxaliplatin 130 mg/m², leucovorin 400 mg/m², fluorouracil bolus 400 mg/m² on day 1, and fluorouracil infusion 2,400 mg/m² for 23-46 h, once every 3-4 weeks). We divided the patients into a training cohort and a validation cohort, used LASSO regression construct prognostic models, predict patient's OS and PFS based on nomograms of models. Patients were divided into high-risk, medium-risk, and low-risk groups according to their respective model risk scores. Kaplan-Meier survival analysis was used to assess the survival time between the three patient cohorts.</p><p><strong>Results: </strong>A total of 333 patients were enrolled in the study and divided into a training cohort and a verification cohort at a ratio of 7:3 (233 in the training cohort and 100 in the validation cohort). The prognostic model we established contained nine prognostic variables. The results of concordance index (C-index) of the OS and PFS prognostic model was 0.75 and 0.71, respectively, higher than that of the TNM staging (0.57 and 0.55, p < 0.001), time-dependent ROC (td-ROC), net reclassification improvement (NRI), integrated discrimination improvement (IDI), and decision curve analysis (DCA) also showed that the model was better than the TNM staging for u-HCC predicting OS and PFS. Subsequently, the model was used to develop a nomogram to predict the individualized prognosis of patients with u-HCC treated with the FOLFOX-HAIC, with a higher net benefit than the TMN staging. According to the risk score, patients were divided into a low-risk group (risk score ≤ 0.458), the medium-risk group (risk score: 0.458-0.799) and the high-risk group (risk score > 0.799). There were significant differences in the OS and PFS between the three groups.</p><p><strong>Conclusions: </strong>The model developed by our team enables risk stratification and personalized prognosis assessment for u-HCC patients undergoing FOLFOX-HAIC treatment, exhibiting superior predictive accuracy and discriminative capability compared to TNM staging.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"112"},"PeriodicalIF":3.4,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual role of Cathepsin S in cutaneous melanoma: insights from mendelian randomization and bioinformatics analysis.","authors":"Linsa Zhou, Qiang Zhou, Qian Guo, Peng Lai, Chen Rui, Wanqing Li, Xuemei Chen, Yue Zhuo, Xiaoping Zhong, Sen Lin","doi":"10.1186/s12885-025-13481-w","DOIUrl":"https://doi.org/10.1186/s12885-025-13481-w","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous melanoma (CM) is strongly associated with ultraviolet (UV) radiation, which contributes to the transformation of melanocytes into melanoma by inducing specific DNA damage. Here, we investigated the causal relationship between CM and genes related to sun-damaged skin, exploring specific target genes through various bioinformatics analyses.</p><p><strong>Methods: </strong>The Gene Expression Omnibus (GEO) database was used to obtain differential genes for CM and normal skin, and the Genome-Wide Association Studies (GWAS) analysis offered summary-level melanoma data for CM. Mendelian randomization (MR) analyses were used to examine the correlated linkage between CM and sun-exposed skin genes. The MR studies were conducted mainly using Inverse Variance Weighting (IVW), MR-Egger, Weighted Median, simple and weighted patterns to predict the correlation between sun-exposed skin and CM. Finally, the role of target genes in CM was revealed by pan-cancer analysis, expression and immune-infiltration evaluations, immuno-checking targeting analysis, immunotherapy response analysis, survival analysis, and protein-protein interactions (PPI) network and enrichment analyses.</p><p><strong>Result: </strong>Using matrix data from the GSE15605, GSE46517, and GSE111452 datasets, bioinformatics analysis revealed 232 differentially expressed genes (DEGs) between CM and typical tissues. MR analysis indicated that only CTSS has a deleterious effect linking skin exposure to sunlight and CM. Analysis of CTSS expression in tumors and tissues, along with the construction of a prognostic model, revealed that CTSS expression was higher in both primary CM and metastatic CM compared to normal skin tissue. However, patients with higher CTSS expression had a higher prognosis. In addition, high CTSS expression was significantly and positively correlated with tumor mutation rate, tumor microenvironment, immune cell infiltration, immune checkpoints and immunotherapy efficacy.</p><p><strong>Conclusion: </strong>Using MR analysis, we found a positive causal relationship between the CTSS gene in sun-exposed skin and CM. Additionally, increased CTSS may provide a basis for biomarker prediction of CM prognosis, immune status and immunotherapy.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"104"},"PeriodicalIF":3.4,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2.","authors":"Hemant M Kocher, Peter Sasieni, Pippa Corrie, Mairéad G McNamara, Debashis Sarker, Fieke E M Froeling, Alan Christie, Roopinder Gillmore, Khurum Khan, David Propper","doi":"10.1186/s12885-024-13333-z","DOIUrl":"https://doi.org/10.1186/s12885-024-13333-z","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic cancer (PDAC: pancreatic ductal adenocarcinoma, the commonest form), a lethal disease, is best treated with surgical excision but is feasible in less than a fifth of patients. Around a third of patients presentlocally advanced, inoperable, non-metastatic (laPDAC), whose stadrd of care is palliative chemotherapy; a small minority are down-sized sufficiently to enable surgical excision. We propose a phase II clinical trial to test whether a combination of standard chemotherapy (gemcitabine & nab-Paclitaxel: GEM-NABP) and repurposing All Trans Retinoic Acid (ATRA) to target the stroma may extend progression-free survival and enable successful surgical resection for patients with laPDAC, since data from phase IB clinical trial demonstrate safety of GEM-NABP-ATRA combination to patients with advanced PDAC with potential therapeutic benefit.</p><p><strong>Methods: </strong>Patients with laPDAC will receive at least six cycles of GEM-NABP with 1:1 randomisation to receive this with or without ATRA to assess response, until progression or intolerance. Those with stable/responding disease may undergo surgical resection. Primary endpoint is progression free survival (PFS) defined as the time from the date of randomisation to the date of first documented tumour progression (response evaluation criteria in solid tumours [RECIST] v1.1) or death from any cause, whichever occurs first. Secondary endpoints include objective response rate (ORR), overall survival (OS), safety and tolerability, surgical resection rate, R0 surgical resection rate and patient reported outcome measures (PROMS) as measured by questionnaire EQ-5D-5L. Exploratory endpoints include a decrease or increase in CA19-9 and serum Vitamin A over time correlated with ORR, PFS, and OS.</p><p><strong>Discussion: </strong>STARPAC2 aims to assess the role of stromal targeting in laPDAC.</p><p><strong>Trial registration: </strong>EudraCT: 2019-004231-23; NCT04241276; ISRCTN11503604.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"106"},"PeriodicalIF":3.4,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quality indicators of supportive care for patients with cancer undergoing treatment: a systematic review.","authors":"Ayako Okuyama, Mai Kuwabara, Sadamoto Zenda","doi":"10.1186/s12885-025-13519-z","DOIUrl":"https://doi.org/10.1186/s12885-025-13519-z","url":null,"abstract":"<p><strong>Background: </strong>Patients need to be supported in combining treatment with daily life. However, measurement of supportive care indicators related to treatment-related side effects is under-reported. This review aimed to identify a list of quality indicators for managing cancer treatment-induced toxicities for adult patients with cancer.</p><p><strong>Methods: </strong>A review was conducted on PubMed, the Cumulative Index to Nursing and Allied Health Literature, the Cochrane Database of Systematic Reviews, and Embase from September 26, 2013 to December 26, 2023. Published English articles that developed or analyzed quality indicators of managing cancer treatment-induced toxicities for adult patients with cancer were selected. The identified indicators were classified according to Donabedian's model for quality of care in healthcare.</p><p><strong>Results: </strong>Forty-two indicators (4 structural, 27 process, and 11 outcome indicators) in 18 articles were identified. Eight articles (44.4%) were from North America, four (22.2%) from Europe, two (11.1%) from Oceania, two (11.1%) from Asia, and one (5.6%) from Africa; 64.3% of the indicators were process indicators based on guidelines. The prevalence of patient symptoms determined using a patient-reported outcome measure was proposed as an outcome indicator. In seven studies (38.9%), these indicators were selected by multidisciplinary experts. None of the studies involved patients or family members in the indicator selection process.</p><p><strong>Conclusion: </strong>The quality of supportive care should be improved by measuring these indicators, considering the patient's needs for supportive care at each hospital such that patients can continue their lives while undergoing treatment.</p>","PeriodicalId":9131,"journal":{"name":"BMC Cancer","volume":"25 1","pages":"103"},"PeriodicalIF":3.4,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}